ArticleAmerican journal of translational research2025
Association between serum response factor, microvascular density, and postoperative recurrence in glioma patients.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the expression of serum response factor (SRF) in glioma patients and its association with microvessel density (MVD) and postoperative recurrence.
methodsThis retrospective study included 100 glioma patients who underwent surgery at the Second Affiliated Hospital of Air Force Medical University between January 2021 and March 2024. Glioma specimens were collected to assess MVD. Meanwhile, preoperative serum samples were analyzed to measure SRF levels. The associations between SRF, MVD, and postoperative recurrence were analyzed. The diagnostic value of SRF and MVD for glioma progression and their predictive potential for postoperative recurrence were evaluated using receiver operating characteristic (ROC) curves. Univariate and multivariate analyses were conducted to identify independent risk factors for postoperative recurrence in glioma patients.
resultsSerum levels of SRF and MVD were significantly higher in high-grade glioma patients than those in low-grade glioma patients. The area under the curve (AUC) for SRF in diagnosing glioma progression was 0.716, while that for MVD was 0.693; however, the combined use of SRF and MVD improved the AUC to 0.760. In glioma, SRF and MVD levels were not correlated with gender, tumor size, or age (
conclusionSRF is highly expressed in high-grade glioma and is positively correlated with MVD. It is closely associated with postoperative recurrence and may serve as a potential biomarker for glioma progression and recurrence prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.